J&J sews up an expanded vaccine pact with Bavarian Nordic, paying $43M for HIV, hep B projects
Just a few days ago researchers at J&J reviewed the latest data from an early-stage study of its HIV vaccine, touting evidence that the mosaic immunogen project it was working on successfully spurred antibodies against the lethal virus in all of the hundreds of patients treated in a Phase I/II trial. Today, the company added some new vaccine tech from Bavarian Nordic that it plans to include in its HIV program, as well as its hep B work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
